According to a recent LinkedIn post from Quell Therapeutics, the company’s CHILL study in CAR‑Treg advanced therapy medicinal products (ATiMP) benefited from an accelerated start‑up at The Newcastle Upon Tyne Hospitals NHS Foundation Trust. The post highlights that early, continuous engagement and a dedicated Operational Group for Advanced Therapies helped move the trial from Local Information Pack to local approval in 36 days, contributing to an overall 113‑day start‑up versus a 150‑day U.K. target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post suggests that Quell is actively building execution capabilities for complex cell therapy trials through close collaboration with leading U.K. research infrastructure, including NIHR Clinical Research Facility, NIHR Industry Hub, Newcastle Advanced Therapies, and Northern Alliance ATTC partners. For investors, the efficient site activation may indicate improving operational risk management and faster clinical timelines, which, if replicated across sites and programs, could enhance Quell’s competitiveness in the cell and gene therapy space and potentially pull forward value inflection points tied to CHILL study progress.